These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 31434472

  • 1. Association between single trough-based area under the curve estimation of vancomycin and treatment outcome among methicillin-resistant Staphylococcus aureus bacteremia patients.
    Makmor-Bakry M, Ahmat A, Shamsuddin A, Lau CL, Ramli R.
    Anaesthesiol Intensive Ther; 2019; 51(3):218-223. PubMed ID: 31434472
    [Abstract] [Full Text] [Related]

  • 2. Impact of initial vancomycin pharmacokinetic/pharmacodynamic parameters on the clinical and microbiological outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children.
    Yoo R, So H, Seo E, Kim M, Lee J.
    PLoS One; 2021; 16(4):e0247714. PubMed ID: 33793589
    [Abstract] [Full Text] [Related]

  • 3. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y, Song KH, Cho Je, Kim HS, Kim NH, Kim TS, Choe PG, Chung JY, Park WB, Bang JH, Kim ES, Park KU, Park SW, Kim HB, Kim NJ, Oh MD.
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Vancomycin Area-Under-the-Curve Dosing Versus Trough Target-Based Dosing in Obese and Nonobese Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia.
    Covvey JR, Erickson O, Fiumara D, Mazzei K, Moszczenski Z, Slipak K, Nemecek BD, Zimmerman DE, Guarascio AJ.
    Ann Pharmacother; 2020 Jul; 54(7):644-651. PubMed ID: 31888350
    [Abstract] [Full Text] [Related]

  • 5. Cost comparison of AUC:MIC- versus trough-based vancomycin monitoring for MRSA bacteremia.
    Beccari MV, Seabury RW, Mogle BT, Kufel WD, Miller CD, Steele JM.
    J Am Pharm Assoc (2003); 2020 Jul; 60(5):729-733. PubMed ID: 32224054
    [Abstract] [Full Text] [Related]

  • 6. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
    Gawronski KM, Goff DA, Brown J, Khadem TM, Bauer KA.
    Clin Ther; 2013 Jun; 35(6):772-9. PubMed ID: 23795575
    [Abstract] [Full Text] [Related]

  • 7. Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-analysis of Observational Studies.
    Prybylski JP.
    Pharmacotherapy; 2015 Oct; 35(10):889-98. PubMed ID: 26497475
    [Abstract] [Full Text] [Related]

  • 8. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S, Tsuji Y, Mizoguchi A, Kasai H, Ishibashi T, Iwamura N, To H.
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [Abstract] [Full Text] [Related]

  • 9. The Impact of AUC-Based Monitoring on Pharmacist-Directed Vancomycin Dose Adjustments in Complicated Methicillin-Resistant Staphylococcus aureus Infection.
    Stoessel AM, Hale CM, Seabury RW, Miller CD, Steele JM.
    J Pharm Pract; 2019 Aug; 32(4):442-446. PubMed ID: 29554847
    [Abstract] [Full Text] [Related]

  • 10. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
    Kullar R, Davis SL, Levine DP, Rybak MJ.
    Clin Infect Dis; 2011 Apr 15; 52(8):975-81. PubMed ID: 21460309
    [Abstract] [Full Text] [Related]

  • 11. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
    Song KH, Kim HB, Kim HS, Lee MJ, Jung Y, Kim G, Hwang JH, Kim NH, Kim M, Kim CJ, Choe PG, Chung JY, Park WB, Kim ES, Park KU, Kim NJ, Kim EC, Oh MD.
    Int J Antimicrob Agents; 2015 Dec 15; 46(6):689-95. PubMed ID: 26555059
    [Abstract] [Full Text] [Related]

  • 12. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
    Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, McNutt LA.
    Clin Infect Dis; 2014 Sep 01; 59(5):666-75. PubMed ID: 24867791
    [Abstract] [Full Text] [Related]

  • 13. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
    Frymoyer A, Guglielmo BJ, Hersh AL.
    Pediatr Infect Dis J; 2013 Oct 01; 32(10):1077-9. PubMed ID: 23652479
    [Abstract] [Full Text] [Related]

  • 14. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
    Clemens EC, Chan JD, Lynch JB, Dellit TH.
    Diagn Microbiol Infect Dis; 2011 Dec 01; 71(4):408-14. PubMed ID: 21924852
    [Abstract] [Full Text] [Related]

  • 15. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Mogle BT, Steele JM, Seabury RW, Dang UJ, Kufel WD.
    Int J Antimicrob Agents; 2018 Dec 01; 52(6):805-810. PubMed ID: 30176357
    [Abstract] [Full Text] [Related]

  • 16. Implementation of vancomycin AUC/MIC dosing vs traditional trough dosing and incidence of acute kidney injury at a rural community hospital.
    McClure S, McElroy L, Gugkaeva Z.
    Am J Health Syst Pharm; 2024 May 24; 81(11):e283-e288. PubMed ID: 38253056
    [Abstract] [Full Text] [Related]

  • 17. Predictive Value of Vancomycin AUC24/MIC Ratio for 30-day Mortality in Patients with Severe or Complicated Methicillin-Resistant Staphylococcus aureus Infections: A Multicenter Retrospective Study.
    Hanai Y, Hashi H, Hanawa K, Endo A, Miyazaki T, Yamaguchi T, Harada S, Yokoo T, Uekusa S, Namiki T, Yokoyama Y, Asakawa D, Isoda R, Enoki Y, Taguchi K, Matsumoto K, Matsuo K.
    Pharm Res; 2024 Jul 24; 41(7):1381-1389. PubMed ID: 38886259
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic/pharmacodynamic analysis of vancomycin in patients with Enterococcus faecium bacteraemia: a retrospective cohort study.
    Tochikura N, Matsumoto C, Iwabuchi S, Aso H, Fukushima S, Ootsuka S, Ooba N, Ishihara M, Nakajima H, Umemura H, Nakayama T.
    Eur J Hosp Pharm; 2024 Aug 22; 31(5):440-446. PubMed ID: 36868850
    [Abstract] [Full Text] [Related]

  • 19. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.
    Brown J, Brown K, Forrest A.
    Antimicrob Agents Chemother; 2012 Feb 22; 56(2):634-8. PubMed ID: 22123681
    [Abstract] [Full Text] [Related]

  • 20. The relationship between trough concentration of vancomycin and effect on methicillin-resistant Staphylococcus aureus in critically ill patients.
    Cheong JY, Makmor-Bakry M, Lau CL, Abdul Rahman R.
    S Afr Med J; 2012 May 25; 102(7):616-9. PubMed ID: 22748440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.